ORIC

Oric Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

4.740

-0.125(-2.570%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

4.850

Open

4.840

VWAP

4.70

Vol

571.97K

Mkt Cap

336.96M

Low

4.535

Amount

2.69M

EV/EBITDA(TTM)

Total Shares

67.42M

142.12M

EV/OCF(TTM)

P/S(TTM)

ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in improving patients' lives by overcoming resistance in cancer. The Company is developing a pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. Its clinical-stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-114, a brain penetrant, orally bioavailable, irreversible inhibitor designed to selectively target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) with high potency towards exon 20 insertion mutations, and ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2).

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

-0.482

-5.39%

-0.469

-4.34%

-0.460

+2.22%

Estimates Revision

Stock Price

Go Down

-39.62%

In Past 3 Month

8 Analyst Rating

297.89% Upside

Wall Street analysts forecast ORIC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ORIC is 18.86 USD with a low forecast of 12.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

0 Hold

0 Sell

Strong Buy

297.89% Upside

Current: 4.740

Low

12.00

Averages

18.86

High

22.00

297.89% Upside

Current: 4.740

Low

12.00

Averages

18.86

High

22.00

HC Wainwright & Co.

Robert Burns

Strong Buy

Maintains

$21 → $22

2025-05-09

Reason

HC Wainwright & Co.

Robert Burns

Price Target

$21 → $22

2025-05-09

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Robert Burns

Strong Buy

Reiterates

$21

2025-05-05

Reason

HC Wainwright & Co.

Robert Burns

Price Target

$21

2025-05-05

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Robert Burns

Strong Buy

Reiterates

$21

2025-02-26

Reason

HC Wainwright & Co.

Robert Burns

Price Target

$21

2025-02-26

Reiterates

Strong Buy

Reason

JP Morgan

Anupam Rama

Buy

Maintains

$21 → $22

2025-02-26

Reason

JP Morgan

Anupam Rama

Price Target

$21 → $22

2025-02-26

Maintains

Buy

Reason

Guggenheim

Michael Schmidt

Strong Buy

Reiterates

n/a

2025-02-26

Reason

Guggenheim

Michael Schmidt

Price Target

n/a

2025-02-26

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Robert Burns

Strong Buy

Reiterates

$21

2025-02-24

Reason

HC Wainwright & Co.

Robert Burns

Price Target

$21

2025-02-24

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Oric Pharmaceuticals Inc (ORIC.O) is -2.58, compared to its 5-year average forward P/E of -6.27. For a more detailed relative valuation and DCF analysis to assess Oric Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.27

Current PE

-2.58

Overvalued PE

-1.64

Undervalued PE

-10.90

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-4.12

Current EV/EBITDA

-1.37

Overvalued EV/EBITDA

1.23

Undervalued EV/EBITDA

-9.46

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00